Endovascular Engineering key facts
as of Oct 2026- Developer of a minimally invasive thrombectomy system designed to remove pulmonary embolisms efficiently while minimizing patient risk.
- Endovascular Engineering is valued at approximately $215.0M as of Oct 2026 (last reported valuation).
- It has raised $141.0M; the latest was Later Stage VC ($80.0M) in Apr 2026.
- Notable investors include Norwest, S3 Ventures, Innovation Partnerships, Gilde Healthcare, Panakes Partners — 12 tracked in total.
- Status: Privately Held (backing).
Endovascular Engineering's last reported valuation, Apr 2026. Nothing priced has surfaced since.
- ·The complete investor list: 12 names
- ·Watch Endovascular Engineering: the Monday email on marks, rounds and moves
Endovascular Engineering funding rounds
No funding rounds for Endovascular Engineering are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Endovascular Engineering leadership
- Daniel RoseChief Executive Officer
Who backs Endovascular Engineering
12+Membership and data by Private Market View
Endovascular Engineering valuation
Endovascular Engineering's last reported valuation was $215 million in Apr 2026. No priced round, secondary trade or fund mark has surfaced since.
Endovascular Engineering investors
12 investors are on record for Endovascular Engineering, including Norwest, S3 Ventures, Innovation Partnerships and Gilde Healthcare. By type, the record holds 4 venture capital firms and 1 private equity firm.
Who runs Endovascular Engineering
1 person is listed on the Endovascular Engineering team: 1 executive, including Daniel Rose (Chief Executive Officer). 1 of them have a verified direct contact on file.
About Endovascular Engineering
Developer of a minimally invasive thrombectomy system designed to remove pulmonary embolisms efficiently while minimizing patient risk. The company offers a small-profile catheter that combines a self-expanding funnel for wide distal clot engagement, dual-action technology that simultaneously agitates and aspirates clots, and integrated navigation controls that allow physicians to maneuver safely through complex vascular pathways, providing precise, controlled, and efficient clot removal during a single procedure, enabling interventional physicians to achieve effective large-bore clot engagement and safe, single-pass procedures through complex vascular anatomies.
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2019
- Employees
- 40
- Website
- endovascularengineering.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.